

MediciNova, Inc.

(MNOV-NASDAQ)

MNOV: Milestone Payments from Legacy Gene Therapy Assets...

Based on our probability adjusted DCF model that takes into account potential future revenues from MN-166 in ALS, progressive MS, and addiction; and MN-001 in NASH and IPF, MNOV is valued at \$26.50/share. This model is highly dependent upon continued clinical success of the company's assets and will be adjusted accordingly based upon future clinical results.

Current Price (04/26/21) **\$4.43**
Valuation **\$26.50**

OUTLOOK

On April 22, 2021, MediciNova, Inc. (MNOV) announced it had recently received two milestone payments from the assignment agreement with Genzyme Corporation, a subsidiary of Sanofi. The milestone payments totaled \$4 million and are the result of the successful achievement of two clinical development milestones for a gene therapy product based on adeno-associated virus vector technology originally developed by Avigen Inc. MediciNova acquired Avigen in 2009. Under terms of the assignment agreement, MediciNova is eligible to receive milestone payments as well as royalties on the sale of products derived from the assignment agreement.

SUMMARY DATA

52-Week High **\$11.00**
52-Week Low **\$4.39**
One-Year Return (%) **-18.72**
Beta **1.45**
Average Daily Volume (sh) **289,472**

Shares Outstanding (mil) **49**
Market Capitalization (\$mil) **\$216**
Short Interest Ratio (days) **N/A**
Institutional Ownership (%) **23**
Insider Ownership (%) **16**

Annual Cash Dividend **\$0.00**
Dividend Yield (%) **0.00**

5-Yr. Historical Growth Rates
Sales (%) **N/A**
Earnings Per Share (%) **N/A**
Dividend (%) **N/A**

P/E using TTM EPS **N/A**
P/E using 2018 Estimate **N/A**
P/E using 2019 Estimate **N/A**

Risk Level **High**
Type of Stock **Small-Blend**
Industry **Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue

(In millions of \$)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2020	0 A	0 A	0 A	0 A	0 A
2021	0 E	0 E	0 E	0 E	0 E
2022					0 E
2023					0 E

Earnings per Share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2020	-\$0.06 A	-\$0.10 A	-\$0.08 A	-\$0.07 A	-\$0.31 A
2021	-\$0.07 E	-\$0.08 E	-\$0.09 E	-\$0.10 E	-\$0.34 E
2022					-\$0.35 E
2023					-\$0.39 E

WHAT'S NEW

Business Update

Milestone Payments from AAV Assets

On April 22, 2021, MediciNova, Inc. (MNOV) **announced** the receipt of two milestone payments that totaled \$4 million as a result of the successful achievement of two clinical development milestones for a gene therapy product based on adeno-associated virus (AAV) vector technology. The AAV technology was developed by Avigen, Inc., which MediciNova acquired in 2009. In 2005, Avigen signed an assignment agreement with Genzyme Corporation, now a subsidiary of Sanofi, for the AAV technology and a large family of patents that included milestone and royalty payments for any products covered by the claims of those patents. In 2014, MediciNova **received** a \$6 million milestone payment from Genzyme related to a gene therapy program under this agreement.

Gene therapy is an exciting area of research as it is becoming possible to replace defective genes that cause debilitating diseases that were once very difficult, if not impossible, to treat. There are a number of vectors available to deliver genes inside of cells, including adenoviruses, AAV, retroviruses, and lentiviruses. AAV is a non-enveloped virus that is able to infect both dividing and non-dividing cells. It contains a small, single-stranded DNA genome that is approximately 4.8 kilobases, which is approximately the limit for the size of a gene that can be packaged efficiently inside it. The genes delivered by AAV persist as extra-chromosomal episomes in the nucleus of transduced cells and do not integrate into host genomes ([Choi et al., 2006](#)). However, transgene expression is potentially long lasting when delivered by AAV, which is an advantage over other vectors such as adenovirus.

Thus far, the FDA has approved two products that utilize AAV as a vector, with a third submission receiving a CRL due to additional data requirements:

- **Luxturna® (voretigene neparvovec-rzyl)**: In December 2017, the FDA approved Luxturna for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, a genetic retinal disorder that affects approximately 1,000 to 2,000 patients in the U.S. Revenues for Luxturna were \$38 million in 2020 (EvaluatePharma).
- **Zolgensma® (onasemnogene abeparvovec-xioi)**: In May 2019, the FDA approved Zolgensma for the treatment of spinal muscular atrophy (SMA) in pediatric patients less than two years old. SMA is caused by a rare mutation in the survival motor neuron 1 gene. Novartis reported revenues for Zolgensma of \$920 million in 2020 with projected revenues of \$2 billion in 2025 (EvaluatePharma).
- **Valoctocogene roxaparvovec**: In August 2020, the FDA issued a complete response letter (CRL) to Biomarin for its severe hemophilia A treatment. The CRL was in regard to additional clinical trial data the agency requested and was not related to any safety issues from the AAV vector.

In December 2020, REGENXBIO, Inc. sold a portion of the royalty rights from the net sales of Zolgensma (derived from its AAV technology) to Healthcare Royalty Management, LLC for \$200 million. REGENXBIO received \$61.6 million in royalties from the sale of Zolgensma in 2020 (approximately 6.7%). We believe this is an excellent example of how a company can monetize rights to approved AAV products.

Conclusion

The rights to the AAV assets that MediciNova acquired from Avigen represent underappreciated upside potential for investors as not many are even aware of their existence. We do not have access to the unredacted agreement between Avigen and Genzyme, thus we do not know the exact amounts that are possible for milestone and royalty payments, or even which specific products in development are covered by the agreement, however the fact that MediciNova recently received two payments for clinical development milestones is very encouraging and means that the potential exists for these payments to occur again in the future. Our valuation remains at \$26.50.

PROJECTED FINANCIALS

MediciNova Inc. Income Statement

MediciNova, Inc.	2020 A	Q1 E	Q2 E	Q3 E	Q4 E	2021 E	2022 E	2023 E
MN-166 (Multiple Sclerosis)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
MN-166 (ALS)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
MN-166 (Addiction)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
MN-001 (NASH)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
MN-001 (IPF)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Grants & Collaborative Revenue	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Total Revenues	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Cost of Sales	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
<i>Product Gross Margin</i>	-	-	-	-	-	-	-	-
Research & Development	\$7.5	\$2.0	\$2.3	\$2.5	\$2.8	\$9.6	\$11.0	\$13.0
General & Administrative	\$6.7	\$1.7	\$1.8	\$1.9	\$2.0	\$7.4	\$8.0	\$9.0
Other Expenses	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Operating Income	(\$14.2)	(\$3.7)	(\$4.1)	(\$4.4)	(\$4.8)	(\$17.0)	(\$19.0)	(\$22.0)
<i>Operating Margin</i>	-	-	-	-	-	-	-	-
Non-Operating Expenses (Net)	\$0.3	\$0.1	\$0.1	\$0.1	\$0.1	\$0.4	\$0.4	\$0.4
Pre-Tax Income	(\$13.9)	(\$3.6)	(\$4.0)	(\$4.3)	(\$4.7)	(\$16.6)	(\$18.6)	(\$21.6)
Income Taxes Paid	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
<i>Tax Rate</i>	0%	0%	0%	0%	0%	0%	0%	0%
Net Income	(\$13.9)	(\$3.6)	(\$4.0)	(\$4.3)	(\$4.7)	(\$16.6)	(\$18.6)	(\$21.6)
<i>Net Margin</i>	-	-	-	-	-	-	-	-
Reported EPS	(\$0.31)	(\$0.07)	(\$0.08)	(\$0.09)	(\$0.10)	(\$0.34)	(\$0.35)	(\$0.39)
<i>YOY Growth</i>	-	-	-	-	-	-	-	-
Basic Shares Outstanding	44,413	48,600	48,800	49,000	49,200	48,900	53,000	55,000

Source: Zacks Investment Research, Inc.

David Bautz, PhD

HISTORICAL STOCK PRICE



Source: Zacks Small Cap Research

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.

SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.